BFRG Bullfrog AI Holdings, Inc. Common Stock
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.73
P/S
59.45
EV/EBITDA
-0.30
DCF Value
$211,251.33
FCF Yield
-78.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
18.4%
Operating Margin
-5273.5%
Net Margin
-5205.9%
ROE
-217.8%
ROA
-109.7%
ROIC
-125.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-1.6M | $— |
| Q4 null | $0.00 | $-1.5M | $— |
| FY null | $116.7K | $-6.5M | $— |
| Q3 null | $83.4K | $-1.6M | $— |
Trading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
-3.00
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.